JAK1 inhibitor abrocitinib for the treatment of steroid-induced rosacea: case series

Frontiers in Medicine

Medicine

Zining Xu¹  Jiawen Wu¹  Bingyang Xu¹  Bin Zhao¹  Shuhong Ye¹  Hong Sun²  Na Wu³ 

[1] Department of Dermatology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China;Department of Neurology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China;Department of Nursing, Xi'an Jiaotong University Medical School, Xi’an, China;

关键词: steroid-induced rosacea;    JAK1 inhibitor;    abrocitinib;    case series;    dermatology treatment;   

DOI  :  10.3389/fmed.2023.1239869

 received in 2023-06-14, accepted in 2023-08-18,  发布年份 2023

来源: Frontiers

【 摘 要 】

BackgroundSteroid-induced rosacea is a severe withdrawal reaction which can occur after the frequent and excessive topical use of steroids on the face. The Janus kinase (JAK)-signal transducers and activators of transcription signaling pathway is involved in many biological processes and may play a role in the development of steroid-induced rosacea.ObjectiveTo observe the efficacy and safety of the JAK1 inhibitor abrocitinib in the treatment of steroid-induced rosacea.MethodsFour Chinese female patients were treated with orally-administered abrocitinib, a selective JAK1 inhibitor with a good safety profile, for steroid-induced rosacea.ResultsAbrocitinib treatment resulted in improved skin condition and lowered Dermatology Life Quality Index scores in each of the four patients. No discomfort was reported and no adverse effects were observed.ConclusionThe JAK1 inhibitor abrocitinib is a promising potential treatment for steroid-induced rosacea.

【 授权许可】

Unknown   
Copyright © 2023 Xu, Xu, Ye, Sun, Zhao, Wu and Wu.